Saturday, February 20, 2021 2:13:55 PM
Let's be fair to BP, they have worldwide distribution and sales forces that can add our vaccines to what they currently offer. I don't expect them to make the vaccine, but they can provide the resources needed to support it's use around the world. Clearly they can support the preparation of the BLA as well as designing and funding additional trials of both DCVax's.
It's not that NWBO cannot do the job without them, they can, but it will be faster, and easier to do with them, and perhaps most importantly they'll provide the funding needed to get new trials started rapidly without massive dilution by the company.
I still believe that DCVax-Direct could be substantially bigger than DCVax-L but the only way to prove it is a substantial size clinical tria
l that incorporates many solid tumors. I believe it's use will prove of benefit prior to surgery in patients with operable tumors in addition to patients with inoperable tumors, but naturally we'll deal with inoperable tumors first.
Gary
It's not that NWBO cannot do the job without them, they can, but it will be faster, and easier to do with them, and perhaps most importantly they'll provide the funding needed to get new trials started rapidly without massive dilution by the company.
I still believe that DCVax-Direct could be substantially bigger than DCVax-L but the only way to prove it is a substantial size clinical tria
l that incorporates many solid tumors. I believe it's use will prove of benefit prior to surgery in patients with operable tumors in addition to patients with inoperable tumors, but naturally we'll deal with inoperable tumors first.
Gary
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
